


US application Serial No. 09/840,503  
Attorney Docket No. QA231

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. - 9. (Canceled).
10. (Previously Amended) A compound of formula (I)



(I)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

X<sup>1</sup> is C=O;

X<sup>2</sup> is CR<sup>3</sup>;

X<sup>3</sup> is -NH-;

X<sup>4</sup> is CR<sup>4</sup>;

X<sup>5</sup> is CR<sup>5</sup>;

X<sup>6</sup> is CR<sup>6</sup>;

R<sup>1</sup> is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, or heteroaryl, provided that when R<sup>1</sup> is alkyl, substituted alkyl or alkenyl, R<sup>2</sup> is not cyano;

R<sup>2</sup> is cyano or a substituted or unsubstituted monocyclic heteroaryl group, provided that when R<sup>2</sup> is cyano R<sup>1</sup> is not alkyl, substituted alkyl or alkenyl;

R<sup>3</sup> is hydrogen, hydroxy, halogen, cyano, CO<sub>2</sub>R<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl or heteroaryl;

R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are independently selected from the group consisting of hydrogen, halogen, nitro, cyano,

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**


$O-R^7$ ,  $NR^8R^9$ ,  $SR^7$ ,  $S(O)R^7$ ,  $SO_2R^7$ ,  $SO_3R^7$ ,  $SO_2NR^8R^9$ ,  $CO_2R^7$ ,  $C(O)NR^8R^9$ ,  $C(O)$ alkyl,  $C(O)$ substituted alkyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

$R^7$ ,  $R^{10}$ , and  $R^{11}$ , are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl,  $C(O)$ alkyl,  $C(O)$ substituted alkyl,  $C(O)$ cycloalkyl,  $C(O)$  substituted cycloalkyl,  $C(O)$ aryl,  $C(O)$ substituted aryl,  $C(O)$ Oalkyl,  $C(O)$ Osubstituted alkyl,  $C(O)$ heterocycloalkyl,  $C(O)$ heteroaryl, aryl, substituted aryl, heterocycloalkyl and heteroaryl; and


$R^8$  and  $R^9$  are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, alkynyl,  $C(O)$ alkyl,  $C(O)$ substituted alkyl,  $C(O)$ cycloalkyl,  $C(O)$ substituted cycloalkyl,  $C(O)$ aryl,  $C(O)$ substituted aryl,  $C(O)$ Oalkyl,  $C(O)$ Osubstituted alkyl,  $C(O)$ heterocycloalkyl,  $C(O)$ heteroaryl, aryl, substituted aryl, heterocycloalkyl, and heteroaryl or  $R^8$  and  $R^9$  taken together with the nitrogen atom to which they are attached complete a heterocycloalkyl or heteroaryl ring[;]

with the following proviso[s]:

- (a) ~~when  $R^1$  is substituted or meta-unsubstituted phenyl,  $R^2$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H, then  $R^3$  is not  $PhCONH$ ,~~



- (b) ~~when  $R^1$  is phenyl substituted with H, F, Cl, Br, I,  $CH_3$ ,  $CF_3$ ,  $OH$ ,  $OCH_3$ ,  $OCF_3$ ,  $OCH_2CH_3$ ,  $NH_2$ ,  $NHCH_3$ ,  $N(CH_3)_2$ , O-benzyl,  $C(=O)R_0$ , or  $C(=O)OR_0$  and  $R_0$  is a lower alkyl group,  $R^2$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H, then  $R^3$  is not~~




~~where Y is  $CH_2$ , O or S, m and n are each greater than 1, and the sum of m and n is between 3 and 6; and~~

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

(c) when  $R^2$  is heteroaryl, at least one of the heteroatoms must be O.

11. (Canceled)

12. (Previously Amended) A compound of Claim 10 of formula (III)



or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

$R^2$  is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl;

$R^3$  is hydrogen, hydroxy,  $NR^8R^9$ , alkyl of 1 to 4 carbons, alkenyl of 2 to 4 carbons, alkynyl of 2 to 4 carbons, substituted alkyl of 1 to 4 carbons, phenyl, substituted phenyl, cycloalkyl of 5 to 7 carbons, substituted cycloalkyl of 5 to 7 carbons, monocyclic heterocycloalkyl and monocyclic heteroaryl;

$R^4$  is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano,  $CF_3$ ,  $OCF_3$ ,  $OCH_3$ ,  $SCH_3$ ,  $S(O)CH_3$ , or  $S(O)_2CH_3$ ;

$R^5$  is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, vinyl,  $CF_3$ ,  $CF_2CF_3$ ,  $CH=CF_2$ ,  $OCH_3$ ,  $OCF_3$ ,  $OCHF_2$ ,  $SCH_3$ ,  $S(O)CH_3$ , or  $S(O)_2CH_3$ ; and

$R^6$  is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano,  $CF_3$ ,  $OCH_3$ ,  $OCF_3$ ,  $SCH_3$ ,  $S(O)CH_3$ , and  $S(O)_2CH_3$ .

13. (Previously Amended) A compound of Claim 12 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

$R^2$  is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl ~~or heteroaryl~~;

$R^3$  is hydrogen, hydroxy, halogen, methyl or  $NR^8R^9$ ;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

$R^4$  is hydrogen;

$R^5$  is halogen, methyl, ethyl, substituted alkenyl, alkyne, OMe or  $OCF_3$ ; and

$R^6$  is hydrogen.

14. (Previously Amended) A compound of Claim 13 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

$R^2$  is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl or substituted 5-oxazolyl;


$R^3$  is hydrogen, hydroxy, halogen or methyl;

$R^4$  is hydrogen;

$R^5$  is halogen, methyl or OMe; and

$R^6$  is hydrogen.

15. (Previously Amended) A compound of Claim 10 of formula (V)




(V)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is  $CH_3$  and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is  $CH_3$ ;

a compound of formula (V) wherein:

$R^1$  is




US application Serial No. 09/840,503  
Attorney Docket No. QA231

and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is


US application Serial No. 09/840,503  
Attorney Docket No. QA231



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is


**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:



US application Serial No. 09/840,503  
Attorney Docket No. QA231


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




US application Serial No. 09/840,503  
Attorney Docket No. QA231

and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503  
Attorney Docket No. QA231


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503  
Attorney Docket No. QA231


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:



US application Serial No. 09/840,503  
Attorney Docket No. QA231


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

US application Serial No. 09/840,503  
Attorney Docket No. QA231

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is


US application Serial No. 09/840,503  
Attorney Docket No. QA231



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;



**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:

$R^1$  is




and  $R^3$  is hydrogen;

US application Serial No. 09/840,503  
Attorney Docket No. QA231

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

a compound of formula (V) wherein:


$R^1$  is



and  $R^3$  is hydrogen;

and a compound of formula (V) wherein:





$R^1$  is








**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

and R<sup>3</sup> is hydrogen.





16. (Previously Amended) A compound of Claim 10 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:








US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231



US application Serial No. 09/840,503  
Attorney Docket No. QA231








US application Serial No. 09/840,503  
Attorney Docket No. QA231













US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231






US application Serial No. 09/840,503  
Attorney Docket No. QA231








US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231



US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231














US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231







US application Serial No. 09/840,503  
Attorney Docket No. QA231




US application Serial No. 09/840,503  
Attorney Docket No. QA231




US application Serial No. 09/840,503  
Attorney Docket No. QA231



US application Serial No. 09/840,503  
Attorney Docket No. QA231



and



17. (Original) A pharmaceutical composition comprising a compound of Claim 10 and a pharmaceutically acceptable carrier.
18. (Canceled).
19. (Original) A pharmaceutical composition comprising a compound of Claim 12 and a pharmaceutically acceptable carrier.
20. (Original) A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.
21. (Original) A pharmaceutical composition comprising a compound of Claim 14 and a pharmaceutically acceptable carrier.
22. (Original) A pharmaceutical composition comprising a compound of Claim 15 and a pharmaceutically acceptable carrier.
23. (Original) A pharmaceutical composition comprising a compound Claim 16 and a pharmaceutically acceptable carrier.
- 24.-29. (Canceled)

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

30. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 10.

31. (Canceled)

32. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 12.

33. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 13.

34. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

35. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

**US application Serial No. 09/840,503**  
**Attorney Docket No. QA231**

36. (canceled).

37. (Previously Added) A method of claim 34 wherein: the phosphodiesterase Type 4 inhibitor is [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone].

38. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17.

39. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17 and another agent known to be useful in treatment of such disorders.

40. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17 and a phosphodiesterase Type 4 inhibitor.

41. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.